Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]

上海南方模式生物科技股份有限公司 独立董事提名人声明与承诺 提名人苏州海望合纵一号股权投资合伙企业(有限合伙), 现提名许庆为上海南方模式生物科技股份有限公司第四届董事 会独立董事候选人,并已充分了解被提名人职业、学历、职称、 详细的工作经历、全部兼职、有无重大失信等不良记录等情况。 被提名人已书面同意出任上海南方模式生物科技股份有限公司 第四届董事会独立董事候选人。提名人认为,被提名人具备独立 董事任职资格,与上海南方模式生物科技股份有限公司之间不存 在任何影响其独立性的关系,具体声明并承诺如下: 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定: (四)中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退(离)休后担任上市公司、基金管理公司独立董 事、独立监事的通知》的规定: (五)中共中央组织部《关于进一步规范党政领导干部在企 业兼职(任职) 问题的意见》的相关规定: (六)中共中央纪委、教育部、监察部《关于加强高等学校 反腐倡廉建设的意见》的相关规定: (七)中国人民银行《股份制商业银行独立董事和外部监事 制度指引》等的相关规定; 一、被提名人具备上市公司运作的基本知识 ...

上海南方模式生物科技股份有限公司 独立董事候选人声明与承诺 本人许庆，已充分了解并同意由提名人苏州海望合纵一号股权投资合伙企业 （有限合伙）提名为上海南方模式生物科技股份有限公司（以下简称"该公司"） 第四届董事会独立董事候选人。本人公开声明，本人具备独立董事任职资格，保 证不存在任何影响本人担任该公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独立 董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 ...

证券代码：688265 证券简称：南模生物 公告编号：2025-058 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开了第三届董事会第二十三次会议，审议通过了《关于控股股东提请召 开临时股东大会的议案》，并于 2025 年 8 月 30 日公告了股东大会召开通知，定 于 2025 年 9 月 23 日召开 2025 年第二次临时股东大会，具体内容详见公司于上 海证券交易所网站（www.sse.com.cn）披露的《第三届董事会第二十三次会议决 议公告》（公告编号：2025-050）和《关于召开 2025 年第二次临时股东大会的 通知》（公告编号：2025-056）。 2025 年 9 月 11 日，公司董事会收到单独持有 11.13%股份的股东苏州海望合 纵一号股权投资合伙企业（有限合伙）（以下简称"海望合纵"）、单独持有 7.37%的股东上海浦东新兴产业投资有限公司（以下简称"浦东新产业"）书面 提交的《海望合纵关于增加 2025 ...

证券代码：688265 证券简称：南模生物 公告编号：2025-059 上海南方模式生物科技股份有限公司 关于2025年第二次临时股东大会增加临时提案 暨股东大会补充通知的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东大会有关情况 1. 股东大会的类型和届次： 2025年第二次临时股东大会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | A 股 | 688265 | 南模生物 | 2025/9/18 | 二、 增加临时提案的情况说明 公司已于2025 年 8 月 30 日公告了股东大会召开通知，合计持有18.5%股份 的股东苏州海望合纵一号股权投资合伙企业（有限合伙）、上海浦东新兴产业投 资有限公司，在2025 年 9 月 11 日提出临时提案并书面提交股东大会召集人。股 东大会召集人按照《上海证券交易所科创板上市公司自律监管指引第 1 号—规范 2. 股东大会召开日期：2025 年 9 月 23 日 3. 股东大会股权登记日： 1. 提 ...

Core Viewpoint - Nanmo Biology's stock price has declined significantly, currently trading at 54.64 yuan, representing a drop of 4.09%, and is in a state of loss since its IPO [1] Company Overview - Nanmo Biology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an initial stock issuance of 19.49 million shares at a price of 84.62 yuan per share [1] - The stock reached its highest price of 82.00 yuan on its first trading day [1] Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 1.649 billion yuan, with a net amount of 1.468 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.068 billion yuan [1] - The company planned to raise 400 million yuan for various projects, including a biological research base and the development of genetically modified animal models [1] - The total issuance costs for the IPO were 181 million yuan, with underwriting fees amounting to 158 million yuan [1]

上海南方模式生物科技股份有限公司 证券代码：688265 证券简称：南模生物 公告编号：2025-057 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 9 日（星期二）至 9 月 15 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海南 方 模 式 生 物 科 技 股 份 有 限 公 司 （ 以 下 简 称 " 公 司 " ） 邮 箱 ir@modelorg.com 提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 公司已于 2025 年 8 月 29 日发布公司《2025 年半年度报告》，为 便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财 务状况，公司计划于 2025 年 9 月 16 日（星期二）13:00-14:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半 ...

Core Viewpoint - The CXO industry is experiencing a recovery after a period of decline, driven by increased profitability among companies and a favorable capital market environment for stock prices [1][4][10]. Group 1: Industry Performance - In the first half of this year, 16 out of 28 A-share CXO companies reported a year-on-year increase in net profit, a significant rise from only 7 companies in the same period last year, indicating a recovery trend [1][3]. - Among the 28 stocks, 8 companies achieved a net profit increase of over 100%, with Chengdu Xian Dao leading at 390.72% [4]. - The total revenue for WuXi AppTec reached approximately 20.8 billion yuan, a year-on-year increase of 20.64%, with a net profit of about 8.56 billion yuan, up 101.92% [4]. Group 2: Market Dynamics - The recovery in the CXO industry is attributed to three main drivers: active pharmaceutical investment and business development transactions, a shift in global pharmaceutical research focus towards biologics and complex molecules, and technological innovations such as AI in drug development [5][11]. - The overall market for CXO services is expanding as pharmaceutical companies increasingly outsource research and development to specialized firms, which helps reduce costs and improve efficiency [5][11]. Group 3: Company-Specific Insights - Despite the overall recovery, some companies like Tigermed reported declines in both revenue and net profit, highlighting a disparity in performance within the industry [6][8]. - Tigermed's revenue fell to approximately 3.25 billion yuan, a decrease of 3.21%, with a net profit of about 383 million yuan, down 22.22% [6][7]. - Companies with diversified client bases and technological advantages are better positioned to capitalize on market recovery, while those reliant on single business lines may face longer adjustment periods [8]. Group 4: Stock Market Performance - All 28 CXO stocks have seen price increases this year, reflecting the industry's recovery [9][10]. - The stock price increases range from 10% to over 100%, with Nanjing Momo Bio leading at a 142.21% increase [10]. - The stock price performance correlates with improved company earnings, indicating a supportive fundamental backdrop for the sector [10].

Core Viewpoint - The CXO industry is experiencing a recovery after a challenging period, with a significant increase in the number of companies reporting profit growth in the first half of the year, indicating a positive trend in the sector [1][3][4]. Financial Performance - In the first half of this year, 16 out of 28 A-share CXO companies reported profit growth, representing approximately 57.14% of the sector [4]. - Notably, 8 companies achieved a doubling of net profit, with Chengdu Xian Dao leading at a 390.72% increase, followed by Nanmo Biology at 298.69% [4]. - Wu Ming Kang De reported the highest net profit among the companies, with approximately 8.56 billion yuan in net profit, a 101.92% year-on-year increase, and revenue of about 20.80 billion yuan, up 20.64% [4]. - Kang Long Hua Cheng, despite a 37% decline in net profit to approximately 701 million yuan, achieved a record high revenue of 6.44 billion yuan, a 14.93% increase [4][5]. Market Dynamics - The recovery in the CXO industry is driven by three main factors: increased activity in pharmaceutical investment and business development transactions, a shift in global pharmaceutical research focus towards biopharmaceuticals and complex molecules, and technological innovations such as AI in drug development [5][6]. - The overall market for CXO services is expanding as pharmaceutical companies increasingly outsource research and development to specialized firms, which helps reduce costs and improve efficiency [5][6]. Performance Disparities - Despite the overall recovery, some companies like Tai Ge Yi Yao and Yi Nuo Si reported declines in both revenue and net profit, indicating uneven recovery across the sector [6][8]. - Tai Ge Yi Yao's revenue fell by 3.21% to approximately 3.25 billion yuan, with a net profit decline of 22.22% to about 383 million yuan, primarily due to decreased income from clinical trial services [6][7]. Stock Market Trends - All 28 CXO stocks have seen price increases this year, reflecting the industry's recovery [9][10]. - The stock price increases range from 10% to over 100%, with Nanmo Biology achieving the highest increase of 142.21% [10]. - The positive stock performance is supported by improved financial results and a favorable global investment environment in pharmaceuticals [10][11]. Future Outlook - The CXO industry is expected to continue its growth trajectory, driven by an aging global population and increasing health demands, although only companies with core competitive advantages will thrive [11][12].

Market Overview - The Shanghai Composite Index closed at 3813.56 points, with a decline of 1.16% [1] - The total trading volume of A-shares reached 23956.82 billion yuan [1] Technical Analysis - A total of 16 A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sichuang Medical (300078) with a distance of -0.91% - Nanmo Biology (688265) with a distance of -0.80% - Shandong Weida (002026) with a distance of -0.75% [1] Individual Stock Performance - Sichuang Medical (300078) saw a decrease of 2.81% with a trading turnover rate of 3.15% [1] - Nanmo Biology (688265) decreased by 0.16% with a turnover rate of 1.39% [1] - Shandong Weida (002026) declined by 2.93% with a turnover rate of 2.90% [1] - Qingda Environmental (688501) dropped by 3.86% with a turnover rate of 1.84% [1] - Pulit (002324) fell by 2.62% with a turnover rate of 2.03% [1] - Other notable declines include: - Meili (000815) down by 4.03% - Hezhong (002383) down by 6.95% [1]